Phase 2 N=326 Low Nicotine Content Cigarettes in Vulnerable Populations: Affective Disorders
Tobacco Use Disorder
Primary: Cigarettes Per Day — 22.54; 14.32; 11.76; 7.63 cigarettes per day
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=114 N-acetylcysteine for Tobacco Use Disorder
Nicotine Dependence · Smoking
Primary: Number of Participants With Biochemically-verified Abstinence From Smoking on Days 1-3 of the Protocol. — 8; 6 Participants
N/A N=137 Varenicline and Motivational Advice for Smokers With Substance Use Disorders
Smoking Cessation · Nicotine Dependence
Primary: 7-day Point-prevalence Smoking Abstinence — 2; 10 participants — p=<0.05
Phase 2 N=326 Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Use Disorder
Tobacco Use Disorder
Primary: Number of Cigarettes Smoked Per Day — 22.54; 14.32; 11.76; 7.63 cigarettes per day
Phase 2 N=94 Proactive Outreach for Smoking Treatment
Smoking, Tobacco · Mental Illness
Primary: Study 3: Smoking Abstinence — 3 Participants
Phase 2 N=10 The Effects of Sedatives on Tobacco Use Disorder
Tobacco Use Disorder
Primary: Side Effects — 1.3; 1.4 score on a scale
N/A N=148 Implementation of Genomics in Substance Use Disorder Treatment
Tobacco Use Disorder · Smoking Cessation · Tobacco Use Cessation
Primary: Change in Use of Smoking Cessation Pharmacotherapy in Past 30 Days — 11; 9; 9; 2 Participants
Phase 4 N=20 Treatment of Nicotine Dependence and Acute Depression
Major Depressive Disorder · Nicotine Dependence
Primary: Hamilton Depression Scale Score — -.5322 percentage of change in depression — p=<.001
N/A N=67 Clinical Trial Tobacco Marijuana
Cannabis Use Disorder · Tobacco Use Disorder
Primary: Tobacco Quit Attempts — 13; 17 Participants — p== 0.33
Phase 4 N=7 Varenicline for Co-occurring Cannabis and Tobacco Use
Cannabis Dependence · Tobacco Dependence
Primary: Enrollment Rate — 7 Participants
Phase 2 N=775 Project 3, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in People With Current Affective Disorders
Tobacco Use Disorder
Primary: Cigarettes Per Day (CPD) — 25.28; 19.95; 17.74 cigarettes per day — p=<0.0001
N/A N=34 Youth Smoking Cessation: Therapy +/- "The Patch"
Smoking
Primary: Acceptance of Nicotine Replacement Therapy — 26 participants
Phase 2 N=38 Treating Smokers With Mental Illness
Smoking Cessation · Cigarette Smoking · Schizophrenia
Primary: 7-Day Point Prevalence Abstinence — 5; 3; 4; 5 Participants
Phase 4 N=323 A Smart Approach to Treating Tobacco Use Disorder in Persons Living With HIV
Tobacco Use Cessation
Primary: Self Reported Reduction in Average Cigarettes Smoked Per Day at 12 Weeks — 5.2; 4.9 cigarettes per day
N/A N=31 Cigarette Smoking in Smokers With and Without Schizophrenia
Tobacco Dependence · Schizophrenia
Primary: End-of-session Carbon Monoxide — 62.7; 43.0 parts per million (ppm)
Phase 2 N=72 Varenicline Treatment for Cannabis Use Disorder
Substance Use Disorder
Primary: Cannabis Withdrawal Symptoms During Active Treatment — 2.23; 3.94; 2.59; 4.07 score on a scale
Phase 4 N=90 Tobacco Use Treatment in Cancer Patients
Smoking, Cigarette
Primary: Smoking 7-Day Point Prevalence at 12 Weeks — 2; 2; 3 Participants
Phase 2 N=232 UW Withdraw From Tobacco Study
Tobacco Dependence
Primary: Change in Total Score on Wisconsin Smoking Withdrawal Scale2 Long (WSWS2-L) — 2.64; 2.36; 2.29; 2.69 score on a scale
Phase 3 N=216 Maintaining Nonsmoking
Nicotine Dependence
Primary: Number of Participants With Reported 7-day Point Prevalence Abstinence at Week 12 — 22; 20; 29; 20 Participants
N/A N=136 Reduced Nicotine Content Cigarettes and Tobacco Switching Behaviors
Tobacco Addiction · Dual Tobacco Use
Primary: Number of Days Using Alternative Products — 14; 26; 20 Number of days
N/A N=188 Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders
Tobacco Dependence
Primary: Plasma Cotinine Concentration — 82.8; 259.0 ng/mL — p=<0.0001
Phase 4 N=30 Tobacco Cessation Treatment Preferences Among Veteran Smokers
Tobacco Use
Primary: Number of Participants Who Report Post-treatment Satisfaction — 15; 10 Participants
N/A N=31 Impact of Exclusive Use of Low Nicotine Cigarettes on Compensatory Smoking
Smoking
Primary: Breath Sample (Expired Carbon Monoxide) — 18.77; 31.07; 25.38; 30.49 parts per million — p=0.92
N/A N=224 Treating Tobacco Dependence in Inpatient Psychiatry - 1
Tobacco Use Cessation · Tobacco Use Disorder
Primary: 7 Day Point Prevalence of Cigarette Abstinence — 3; 14; 6; 14 Participants — p=0.018
Phase 4 N=300 Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers
Nicotine Dependence · Major Depressive Disorder
Primary: Bioverified Point-prevalence Abstinence at 27 Weeks — 6; 3; 13; 13 Participants
Phase 2 N=775 Project 2, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Opioid Abusers
Tobacco Use Disorder
Primary: Cigarettes Per Day (CPD) — 25.28; 19.95; 17.74 cigarettes per day — p=<0.0001
N/A N=103 Smoking Cessation in Alcoholics
Smoking Cessation · Alcohol Consumption
Primary: Number of Smoke-free Patients — 0; 3 participants — p==.111
N/A N=832 Testing an Organizational Change Model to Address Smoking in Mental Healthcare
Nicotine Dependence
Primary: Client Reported Tobacco Medications — 48; 28; 62; 24 Participants
N/A N=104 Accelerated iTBS in Smoking Cessation
Nicotine Dependence · Smoking Cessation
Primary: Self-reported Nicotine Consumption — 27.55; 26.83; 30.00 cigarettes/day
Phase 4 N=181 Cannabis and Tobacco Co-use Study
Tobacco Use Disorder
Primary: Number of Participants With Biologically Verified 7-day Point Prevalence Tobacco Abstinence at the End of Treatment (Week 12) — 30; 40; 36; 42 Participants